Background: Efforts to reduce labor duration for both mother and fetus are valuable. The current study aimed to evaluate the impact of varying concentrations of Hyoscine Butylbromide on labor. Methods: The study involved 60 first-time pregnant women at full term gestation, who were divided into two groups, each containing 30 individuals. In Group I, an intravenous dose of 40 mg of Hyoscine Butylbromide (HBB) was administered during the early active phase of labor, while in Group II, a 60 mg intravenous HBB dose was administered. Results: Each of the two groups comprised 30 patients. In Group I, patients were administered 40 mg of intravenous Hyoscine Butylbromide (HBB), while in Group II, patients received 60 mg of intravenous HBB. The mode of delivery differed slightly between the two groups, with 5 cases of abdominal delivery in Group I and 4 in Group II. Vaginal delivery was observed in 10 cases in Group I and 11 in Group II. It's worth noting that the difference between the groups was not statistically significant (P > 0.05). Conclusion: The authors of the study concluded that both 40 mg and 60 mg of Hyoscine Butylbromide (HBB) were effective at their respective concentrations. Importantly, there was no statistically significant difference in their outcomes.